

Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences

Neoplastic Diseases: A Mini-Review

Vivek Joyal*

St. John's college of pharmacy, Warangal, India.

Review Article

Received:15-03-2016

Revised: 22-03-2016

Accepted:28-03-2016

***Corresponding author:**

Vivek Joyal, Department of Pharmacology, St. John's college of pharmacy, Warangal, Telangana, India, Tel: +91 80199 05965; +91 95424 22283;

E-mail: vivek11vicky62@gmail.com

Keywords: Tumor, Neoplasm, Chemotherapy

ABSTRACT

Neoplastic infection is the intemperate division of cells, because of an assortment of causes, that outcomes in the development of atypical assemblages of tissue called neoplasms. A neoplasm can shape practically any place in the body and is normally alluded to as a tumor. Despite the fact that the words neoplasm or tumor have a tendency to be utilized to some degree synonymously with growth, neoplasms can likewise pretty much as ordinarily be kind or premalignant as dangerous. There are various potential causes, side effects, and determination systems of neoplastic malady and in addition distinctive treatment alternatives and forecasts.

INTRODUCTION

Neoplastic ailment is the intemperate division of cells, because of an assortment of causes, that outcomes in the development of atypical groups of tissue called neoplasms. A neoplasm can frame for all intents and purposes anyplace in the body and is ordinarily alluded to as a tumor. Despite the fact that the words neoplasm or tumor have a tendency to be utilized to some degree synonymously with disease, neoplasms can likewise pretty much as ordinarily be kindhearted or premalignant as dangerous. There are various potential causes, side effects, and finding strategies of neoplastic infection and in addition diverse treatment choices and forecasts [1-10].

Various danger elements have been distinguished for the improvement of this condition. Way of life propensities, for example, over the top liquor utilization, smoking, and weight are all known not to the illness [11-13]. Moreover, hereditary inclination and invulnerable framework difficulties are additionally figures. Neoplasms are additionally brought about by infections, for example, human papillomavirus (HPV) and hepatitis B. Concoction and natural poisons, radiation, and over the top sun introduction are likewise known not parts [14-20].

The side effects of neoplastic sickness change in both their sort and seriousness. They have a tendency to be identified with the area of the neoplasm and can frequently be to some degree summed up [15]. Run of the mill side effects can incorporate frailty, weariness, and night sweats, with different side effects, for example, shortness of breath, loose bowels, and weight reduction additionally being regular. Now and then, there are noticeable or acceptable manifestations, including skin sores or an irregularity under the skin. At times, the infection is asymptomatic, or the manifestations may not be obvious until the sickness is all around cutting edge [21-28].

This condition is analyzed in various ways. The most corroborative technique is biopsy, where the cell parts of the neoplasm are analysed [29,30]. This procedure can affirm the conclusion furthermore decide the threat and kind of development. Automated hub tomography (CAT), attractive reverberation imaging (MRI), and positron

emanation tomography (PET) are utilized after determination to outline the sum of the area, size, and conceivable spread of the illness. Blood tests, including both for general blood profile and that to for tumor markers, are likewise done, and bone marrow biopsies are basic for neoplastic ailments, for example, leukemia [31-40].

Treatment choices for the condition fluctuate with the kind of development. Kind neoplasms for the most part don't require any treatment, in spite of the fact that they might be expelled on the off chance that they are applying weight on organs or nerves. Surface injuries may require corrective expulsion. Dangerous types of neoplastic infection normally require surgery, radiation, or chemotherapy and frequently a blend of each of the three. On the off chance that the disease has spread to organs, for example, the lymph hubs, these are additionally regularly evacuated to forestall further spread [41-50].

The visualization for patients influenced with this illness differs in light of the level of harm, sort, and area of the neoplasm. An amiable neoplasm has a superior visualization than harmful conditions, however even dangerous neoplasms are regularly treatable. A few structures and areas are simpler to treat than others and react better to various treatment choices [51-55].

TYPES OF NEOPLASTIC DISEASES

A neoplasm can be considerate, conceivably threatening, or harmful (cancer).

- Considerate tumors incorporate uterine fibroids and melanocytic nevi (skin moles). They are outlined and restricted and don't change into cancer.
- Possibly dangerous neoplasms incorporate carcinoma in situ. They are limited, don't attack and devastate yet in time, may change into a disease.
- Harmful neoplasms are generally called tumor. They attack and wreck the encompassing tissue, may frame metastases and, if untreated or inert to treatment, will demonstrate lethal.
- Optional neoplasm alludes to any of a class of dangerous tumor that is either a metastatic branch of an essential tumor, or an obviously random tumor that expansions in recurrence taking after certain disease medications, for example, chemotherapy or radiotherapy.
- Once in a while there can be a metastatic neoplasm with no known site of the essential tumor and this is classed as a disease of obscure essential beginning.

REASONS

A neoplasm can be brought on by an anomalous multiplication of tissues, which can be created by hereditary transformations. Not a wide range of neoplasms cause a tumorous abundance of tissue, notwithstanding, (for example, leukemia or carcinoma in situ) [55-60]. As of late, tumor development has been concentrated on utilizing science and continuum mechanics [61]. Vascular tumors (shaped from veins) are along these lines took a gander at as being amalgams of a strong skeleton framed by sticky cells and a natural fluid filling the spaces in which cells can grow. Under this kind of model, mechanical burdens and strains can be managed and their impact on the development of the tumor and the encompassing tissue and vasculature illustrated [11,62]. Late discoveries from trials that utilization these models demonstrate that dynamic development of the tumor is confined to the external edges of the tumor and that solidifying of the hidden ordinary tissue restrains tumor processing. The ultimate conditions that are not connected with an anomalous expansion of tissue, (for example, sebaceous sores) can likewise present as tumors, in any case, however have no harmful potential. Bosom growths (as happen normally amid pregnancy and at different times) are another case, as are other embodied glandular swellings (thyroid, adrenal organ, pancreas; Figure1-3) [63-80].

Epitomized hematomas, embodied necrotic tissue (from a bug chomp, outside body, or different harmful instrument), keloids (discrete abundances of scar tissue) and granulomas may likewise present as tumors. Discrete limited developments of typical structures (ureters, veins, intrahepatic or extra hepatic biliary channels, aspiratory incorporations, or gastrointestinal duplications) because of surge blocks or narrowing's, or irregular associations, may likewise present as a tumor. Illustrations are arteriovenous fistulae or aneurysms (with or without thrombosis), intestinal duplications, and pneumonic considerations as seen with cystic fibrosis. It can be hazardous to biopsy various sorts of tumor in which the spillage of their substance would conceivably be calamitous. At the point when such sorts of tumors are experienced, indicative modalities, for example, ultrasound, CT filters, MRI, angiograms, and atomic medication sweeps are utilized before (or amid) biopsy and/or surgical investigation/extraction trying to keep away from such serious complexities. The way of a tumor is

controlled by imaging, by surgical investigation, and/or by a pathologist after examination of the tissue from a biopsy or a surgical example [80-100].



Figure 1: Colon cancer.




Figure 2: Benign pancreatic mucinous cystic neoplasm.




Figure 3: Histopathology of Pancreatic solid pseudo papillary neoplasm.

CONCLUSION

Pericardial neoplastic contribution ought to dependably be suspected in patients giving neoplasia, since signs and manifestations are non-particular, as are general test discoveries. Along these lines, the illness must be analyzed if there is a clinical suspicion. The finding can be made more exact with a pericardial biopsy and cytological examination, especially with the guide of pericardioscopy. Analysis and treatment of neoplastic pericarditis is imperative in light of the fact that, if undetected, it can bring about more prominent mortality in those patients who have it.

REFERENCES

1. Bisen PS. Nutritional Therapy as a Potent Alternate to Chemotherapy against Cancer. *J Cancer Sci Ther.* 2016; 8: e135.
2. Geleta B, et al. N-myc Downstream Regulated Gene (NDRG): Role in Cancer Metastasis Suppression and as Drug Target in Cancer Therapeutics. *J Cancer Sci Ther.* 2016; 8: 154-159.
3. Geleta B, et al. Cyclic Dependent Kinase (CDK): Role in Cancer Pathogenesis and as Drug Target in Cancer Therapeutics. *J Cancer Sci Ther.* 2016; 8: 160-167.
4. Murugan NJ, et al. Differentiation of Malignant Compared to Non-Malignant Cells by Their Bio- Photon Emissions May Only Require a Specific Filter around 500 nm. *J Cancer Sci Ther.* 2016; 8: 168-169.
5. Brafford P, et al. 1205Lu is Human Melanoma Depending on the Source. *J Cancer Sci Ther.* 2016; 8: 113.
6. Ahmad A, et al. Kras, Braf, PIK3CA and EGFR Gene Mutations are Associated with Lymph Node Metastasis and Right Sided Colon Carcinoma. *J Cancer Sci Ther.* 2016; 8: 122-129.
7. Nyamai DW, et al. Herbal Management of Benign Prostatic Hyperplasia. *J Cancer Sci Ther.* 2016; 8: 130-134.
8. Ahmad F, et al. CD24 Induces the Activation of β -Catenin in Intestinal Tumorigenesis. *J Cancer Sci Ther.* 2016; 8: 135-142.
9. Attaallah W, et al. A Fibrosarcomatous ("High-Grade") Variant of Dermatofibrosarcoma Protuberans (DFSP). *J Carcinog Mutagen.* 2014; S4: 007.
10. Kang CM, et al. Anticancer Effect of *Phellinus linteus*; Potential Clinical Application in Treating Pancreatic Ductal Adenocarcinoma. *J Carcinogene Mutagene.* 2013; S9: 001.
11. Mannan A, et al. p53 R72P Alone and in Combination with MDM2 SNP T309G is Associated with Colon Carcinoma Incidence and Survival. *J Carcinog Mutagen.* 2016; 7: 266.
12. Ichihara H, et al. Negatively Charged Cell Membranes-Targeted Highly Selective Chemotherapy with Cationic Hybrid Liposomes against Colorectal Cancer In Vitro and In Vivo. *J Carcinog Mutagen.* 2016; 7: 267.
13. Manzo C. Cancerogenesis and Polymyalgia Rheumatica. *J Carcinog Mutagen.* 2016; 7: 268.
14. Shrihari TG. Inflammation Related Cancer - Highlights. *J Carcinog Mutagen.* 2016; 7: 269.
15. Al-Dabbagh AR, et al. Human Papillomavirus (HPV) and Oral Squamous Cell Carcinoma in a UK Population: Is there an Association?. *J Carcinog Mutagen.* 2016; 7: 270.
16. Tsvetkov Ch, et al. Survival Rate after Individualized Approach in Treatment of Vulvar Cancer: A Ten- Year Single Institution Experience. *J Clin Exp Oncol.* 2016; 5: 3.
17. Romeira D, et al. Tumor Infiltrating Lymphocytes and Axillary Lymph Node Positivity: A Systematic Review. *J Clin Exp Oncol.* 2016; 5: 2.
18. Norollahi SE, et al. The Role of MicroRNAs in Cancer Progression. *J Clin Exp Oncol.* 2016; 5: 2.
19. Kumar R, et al. Quantum Magnetic Resonance Therapy: Targeting Biophysical Cancer Vulnerabilities to Effectively Treat and Palliate. *J Clin Exp Oncol.* 2016; 5: 2.
20. Parvathi MVS, et al. Micro RNA-142-5p Profile as a Predictor of Tumor Markers Regulation in Different Histological Grades of Human Breast Carcinoma. *J Clin Exp Oncol.* 2016; 5: 2.
21. Malshe AG. Hydrogen ion/Proton Dynamics: A Possible Therapeutic Approach in Malignancy Treatment. *J Clin Exp Oncol.* 2016; 5: 1.
22. Shin DG, et al. A Methylation Profile of Circulating Cell Free DNA for the Early Detection of Gastric Cancer and the Effects after Surgical Resection. *J Clin Exp Oncol.* 2016; 5: 1.
23. Guest TC and Rashid S. Anticancer Laccases: A Review. *J Clin Exp Oncol.* 2016; 5: 1.
24. Kunos CA and Vikram B. Is There A Role for Radiotherapy In Experimental Therapeutic Drug Development? *. OMICS J Radiol.* 2016; 5: e140.
25. Greenwood HI, et al. Achieving Consistent, Homogeneous, Dark Fat Suppression on Bilateral Breast MRI at 3.0 Tesla in the Clinical Setting. *OMICS J Radiol.* 2016; 5: 230.
26. Chatzoglou V, et al. Management and Optimisation of the Dose in Computed Tomography via a Dose Tracking Software. *OMICS J Radiol.* 2016; 5: 227.
27. Kiran T and Aruna T. Diagnosis and Treatment of Radiation Therapy induced Ocular Surface Disorders. *OMICS J Radiol.* 2015; 5: e138.

28. Abdollahi H and Malekzadeh M. Radiophilia: A Common Case of Excessive Radiation Exposure in Healthcare. *OMICS J Radiol.* 2016; 5: e139.
29. Ramakrishnan P and Valambath S. Atypical Radiographic Appearance in Cleidocranial Dysplasia. *OMICS J Radol.* 2016; 5: 221.
30. Fu J, et al. Staging Hepatocellular Carcinoma with Gadolinium-Ethoxybenzyl Diethylenetriaminepentaacetic Acid -Enhanced Magnetic Resonance Imaging: A Comparison with Multi-Detector Row Computed Tomography. *OMICS J Radiol.* 2016; 5: 222.
31. López-García, et al. Injury of the Artery Epigastrica Low after Channeling of Vascular Accesses. 2016; 5: 223.
32. Macri F, et al. Facing Radiologists' Reluctance of a Degraded although Diagnostic Image Quality of Low/Ultra-low-dose CT: Our Experience. *OMICS J Radiol.* 2016; 5: 224.
33. Liu X, et al. Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ≥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. *OMICS J Radiol.* 2016; 5: 225.
34. Darwish HS. Duplication of Gall bladder: Review of Literature and Report of a Case. *OMICS J Radiol.* 2016; 5: 226.
35. Ahmadvand A and Daliri MR. A Review on Texture Analysis Methods in Biomedical Image Processing. *OMICS J Radiol.* 2016; 5: e136.
36. Kirste S, et al. Abdominal Stereotactic Body Radiotherapy: Local Control and Correlation to Biologically Equivalent Dose. *OMICS J Radiol.* 2016; 5: 216.
37. Nasri F, et al. Evaluation of Multi-Slice Computed Tomography in Assessment of Cochlear Implant Electrode Position: A Pictorial Essay. *OMICS J Radiol.* 2016; 5: 217.
38. Wei K, et al. Potential Application of Radiomics for Differentiating Solitary Pulmonary Nodules. *OMICS J Radiol.* 2016; 5: 218.
39. Visalli C, et al. Accuracy of Cystosonography without Voiding Phase in the Diagnosis of Vesicoureteral Reflux in Children: A Variant of the Original Technique. *OMICS J Radiol.* 2016; 5: 219.
40. Sellem DB, et al. Predictive Value of 1 Month Postoperative MRSI and FDGPET Evaluations of Glioblastomas. *OMICS J Radiol.* 2016; 5: 220.
41. Rucinska M, et al. Quality of Life and Sexual Activity after Stereotactic ypofractionated Radiotherapy of Prostate Cancer Patients. *J Integr Oncol.* 2016; 5: 173.
42. Heidari A. Linear and Non-Linear Quantitative Structure-Anti-Cancer-Activity Relationship (QSACAR) Study of Hydrous Ruthenium (IV) Oxide (RuO₂) Nanoparticles as Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Anti-Cancer Nano Drugs. *J Integr Oncol.* 2016; 5: e110.
43. Qun W, et al. Effective Personalized Treatment of Advanced Hepatic Carcinoma based on Sorafenib. *J Integr Oncol.* 2016; 5: 164.
44. Nekkanti S, et al. An Unusual Presentation of Non Union of Patella with Full Range of Movements of the Knee Joint. *J Integr Oncol.* 2016; 5: 165.
45. Recchia F, et al. Long-term Follow-up of Pegylated Liposomal Doxorubicin and Oxaliplatin in Recurrent Ovarian Cancer. *J Integr Oncol.* 2016; 5: 166.
46. Yonemura Y, et al. Risk Factors for Recurrence after Complete Cytoreductive Surgery and Perioperative Chemotherapy in Peritoneal Metastases from Gastric Cancer. *J Integr Oncol.* 2016; 5: 167.
47. Ruzzenente A, et al. Risk A Novel Prognostic Score based on Serum Alpha-Fetoprotein, Number of Nodules, and MYC Gene Status Predicts Prognosis of Patients after Liver Resection for Hepatocellular Carcinoma. *J Integr Oncol.* 2016; 5: 168.
48. Hosiriluck N and Jones C. Emergence of Squamous Cell Carcinoma during Treatment of Basal Cell Carcinoma with Vismodegib. *J Integr Oncol.* 2016; 5: 169.
49. Elm'hadi C, et al. A Huge Malignant Peripheral Nerve Sheath Tumor Revealing Von Recklinghausen's Disease. *J Integr Oncol.* 2016; 5: 170.
50. Masuda H, et al. Expression of Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) in Human Renal Cell Carcinoma. *J Integr Oncol.* 2016; 5: 171.
51. Carr BI, et al. An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels. *J Integr Oncol.* 2016; 5: 172.

52. Filho RSO, et al. Main Barriers in Control of Energy-Protein Deficit in Critical Oncologic Patient at Nutritional Risk. *J Integr Oncol.* 2016; 5: 156.
53. Mastrangelo D, et al. The Cure from Nature: The Extraordinary Anticancer Properties of Ascorbate (Vitamin C). *J Integr Oncol.* 2016; 5: 157.
54. Lai-Tiong F. Chemotherapy-Induced Nausea and Vomiting: An Oncology-Day Unit Experience. *J Integr Oncol.* 2016; 5: 158.
55. Mukherjee G, et al. Analysis of Clinico-Pathological Characteristics of Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-Types. *J Integr Oncol.* 2016; 5: 159.
56. Barreca S, et al. Huge Liposarcoma of the Forefoot: A Case Report. *J Integr Oncol.* 2016; 5: 160.
57. Giulio GM, et al. Local Resections and Prosthetic Reconstructions in Solitary Bone Metastases of the Limbs According to Histotypes. *J Integr Oncol.* 2016; 5: 161.
58. Couderc AL, et al. Prognostic Factors in Elderly Patients with Multiple Myeloma Treated with Weekly Bortezomib. *J Integr Oncol.* 2016; 5: 162.
59. Cheng Q, et al. Meta-analysis of CXCR7 Expression Related to Clinical Prognosis in Cancers. *J Integr Oncol.* 2016; 5: 163.
60. Yu G. Metformin as an Anticancer Drug: A Commentary on the Potential Therapeutic Strategy and Underlying Mechanism of Metformin in Gastric Cancer. *Chemo Open Access.* 2016; 5: 202.
61. Mukherjee R, et al. Current Understanding of Epidemiology, Genetic Etiology and Treatment of Gliomas from Indian Population. *Chemo Open Access.* 2016; 5: 203.
62. Rashid OM, et al. A Systematic Approach to Preclinical Trials in Metastatic Breast Cancer. *Chemo Open Access.* 2016; 5: 204.
63. Xu Y, et al. Interferon- γ Upregulates SOCS3 Expression to Reduce Cisplatin Chemoresistance in Non-Small Cell Lung Cancer A549 Cells. *Chemo Open Access.* 2016; 5: 205.
64. Panneerselvam J, et al. Fanconi Anemia Group D2 Protein Participates in Replication Origin Firing. *Chemo Open Access.* 2016; 5: 206
65. Heidari A. A Chemotherapeutic and Biospectroscopic Investigation of the Interaction of Double-Standard DNA/RNA-Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh₂O₃) Nanoparticles as Anti-Cancer Drugs for Cancer Cells' Treatment. *Chemo Open Access.* 2016; 5: e129.
66. Principe M, et al. Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer. *Chemo Open Access.* 2016; 5: 188.
67. Bagella L and Marchesi I. SFK Inhibitors as New Strategy for RMS Treatment. *Chemo Open Access.* 2016; 5: 189.
68. Zhang M, et al. Targeting Human β -Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment. *Chemo Open Access.* 2016; 5: 190.
69. Di Agostino S and Blandino G. Genomic Instability: The Pivotal Role of Mutant p53 in Human Cancers. *Chemo Open Access.* 2016; 5: 191.
70. Wang Y, et al. Raltitrexed based Transcatheter Arterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma: A Single-center Randomized Controlled Study. *Chemo Open Access.* 2016; 5: 192.
71. Cheng H, et al. A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient. *Chemo Open Access.* 2016; 5: 193.
72. Ullah E, et al. Prognostic Role of Microvascular Density and Mucin Production in 56 Cases of Adenocarcinoma of Lung- An Experience from a Center in Lahore, Pakistan. *Chemo Open Access.* 2016; 5: 194.
73. Zhu M, et al. Alpha Fetoprotein Plays Antagonistic Role in Benzyl-Isothiocyanate Arresting Cell Cycle in Liver Cancer Cells. *Chemo Open Access.* 2016; 5: 195.
74. Lucibello M and De Braud F. Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. *Chemo Open Access.* 2016; 5: 196.
75. Kubo A, et al. NK-1 Receptor Antagonists: Who Truly Need them and their Cost- Effectiveness Analysis?. *Chemo Open Access.* 2016; 5: 197.
76. Fedele M, et al. The Tumor Suppressive Role of PATZ1 in Thyroid Cancer: A Matter of Epithelial-Mesenchymal Transition. *Chemo Open Access.* 2016; 5: 198.

77. Dong J, et al. Targeting ROS for Cancer Therapy. *Chemo Open Access*. 2016; 5: 199.
78. Zhu HH, et al. CD34-Negative is Highly Associated with T (15;17), T (V; 11q23) and the NPM1-Mutation Subtypes in 343 Newly Diagnosed Patients with Acute Myeloid Leukemia . *Chemo Open Access*. 2016; 5: 200.
79. Yang H, et al. FBXW7 Pathway Functions as a Promising Therapeutic Target of Cholangiocarcinoma. *Chemo Open Access*. 2016; 5: 201.
80. Jyoti BS. Accuracy of MRI for Prediction of Response to Neo-Adjuvant Chemotherapy in Triple Negative Breast Cancer Compared to Other Molecular Types. *Chemo Open Access*. 2015; 5: 175.
81. Cheng Liu. Limb Salvage Strategy by Intra-Arterial Chemotherapy for Local Recurrent Osteosarcoma in Extremities. *Chemo Open Access*. 2015 5: 176.
82. Christos K. Follow up of Testicular Tumours for How Long it is Necessary?. *Chemo Open Access*. 2015; 5: 177.
83. Sharma and Cheng. New & Emerging Drugs for Squamous Cell Lung Cancer. *Chemo Open Access*. 2015; 5: 178.
84. De Domenico EBL, et al. Professional Competence in Oncology: Challenges for Education . *Chemo Open Access*. 2015; 5: 179.
85. Niang M, et al. Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour. *Chemo Open Access*. 2015; 5: 180.
86. Soldà C, et al. Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular Carcinoma. *Chemo Open Access*. 2015; 5: 181.
87. Xu M, et al. Aggressive Natural Killer Cell Leukemia Secondary to Hodgkin Lymphoma: a Case Report and Review of the Literature. *Chemo Open Access*. 2016; 5: 182.
88. Yasuhiro Kodera. A search for Optimal Cytotoxic Drug as a Partner for the Oral Fluoropyrimidines in the Postoperative Adjuvant Chemotherapy for Gastric Cancer. *Chemo Open Access*. 2016; 5: 183.
89. Provenzano M and Xavier Keller E. The Potential Therapeutic Usefulness of Targeting BK Polyomavirus in Prostate Cancer. *Chemo Open Access*. 2015; 5: 184.
90. Chen Y and Wan X. Lmdd-MPPFG Prevents HCC Occurrence through Dendritic Cells Related Signaling Pathways. *Chemo Open Access*. 2016; 5: 185.
91. Wang YM, et al. A Study Design: Concurrent EGFR-TKI and Thoracic Radiotherapy as Firstline Treatment of Stage IV NSCLC Patients with EGFR Active Mutations (CERTAIN Study). *Chemo Open Access*. 2016; 5: 186.
92. Akihiko Osaki. Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy. *Chemo Open Access*. 2016; 5: 187.
93. Attia TH. Childhood Cancer Care in Developing Countries; Challenge. *Adv Oncol Res Treat*. 2016; 1: e101.
94. Priyanka D. Targeted Therapies in Cancer. *Adv Oncol Res Treat*. 2016; 1: e102.
95. Sugarbaker PH and Glehen O. Management of Unexpected Peritoneal Metastases With Primary Colorectal Cancer Using Second-Look Surgery With HIPEC. *Can surg*. 2015; 1: 101.
96. Mondal T, et al. Argonaute-1 Machinery Silent Cancer Noises. *Can surg*. 2016; 1: 102.
97. Chhabra S, et al. Staging Issues in Cervical Cancer. *Can Surg*. 2016; 1: 104.
98. Ian SF. Medico-legal Aspects of Delay in Diagnosis of Breast Cancer. *Can Surg*. 2016; 1: 103.
99. Garcia SB, et al. Neuropeptides in the Development of Colon Cancer. *Can Surg*. 2016 1: 104.
100. Videa-Irias EO. Multiple Myeloma, A Patient with Multiple Infections: A Case Report. *Arch Can Res*. 2016;4:3.